RCT | Vorasidenib enhances PFS in IDH1/2-mutant low-grade glioma, trial methods debated online

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Vorasidenib Delays Disease Progression or Death in Patients With Grade 2 IDH-Mutated Glioma – The ASCO Post

Commentary on Twitter questioning study methodology (thread – click for more)

This is a rather troubling study. The fact that it got published in @NEJM is concerning, to say the least

Astonishing cost of $16 000/month for a drug administered continuously until disease progression in a trial with a dubious endpoint and flawed design

Here are my thoughts: https://t.co/E3QtZfEyQw

— Stanislav (Stas) Lazarev, MD (@StasLazarev) June 5, 2023